Expression and significance of Th9 and Th17 in the peripheral blood of patients with cryptococcal meningitis

Abstract

Abstract:

Objective To explore the role of Th9 and Th17 cells in the pathogenesis of CM by mesureing the ratio of Th9 and Th17 cells in CD4+T lymphocyte of patients with cryptococcal meningitis (CM).Methods Twelve CM patients without antifungal treatment and 12 healthy controls were selected. The peripheral blood was collected from patients prior treatment and three weeks after treatment and the healthy controls. The ratio of Th9 and Th17 cells in peripheral blood were analyzed by flow cytometry.Result The ratio of Th17 cells in patients with CM before treatment was less than those of healthy people, and patients who received treatment showed the increased level of Th17 cells which was higher than those in patients before treatment and the healthy controls. The ratioof Th9 also increased in the patients who received treatment while there was no significant different between the patients before treatment and the healthy controls.Conclusion Th17 immune pathway is an important immune mechanism against Cryptococcus infection in patients with CM. The lack of Th17 cells may play a role in the pathogenesis and treatment-resistant of CM.

Key words: cryptococcal meningitis, Th cells, Th17, Th9, Cryptococcus

CLC Number:

R519.4

LEI Wen-zhi, SANG Jun-jun, PAN Wei-hua, LIAO Wan-qing. Expression and significance of Th9 and Th17 in the peripheral blood of patients with cryptococcal meningitis[J]. Chinese Journal of Mycology, 2014, 9(2): 79-82,95.

References

[1] Park BJ, Wannemuehler KA, Marston BJ,et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS[J]. AIDS (London, England),2009,23(4): 525-530.
[2] Veldhoen M, Uyttenhove C, van Snick J, et al. Transforming growth factor-beta‘reprograms’the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset[J]. Nat Immunol,2008,9(12): 1341-1346.
[3] Khader SA, Cooper AM. IL-23 and IL-17 in tuberculosis[J]. Cytokine,2008,41(2): 79-83.
[4] Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells[J]. Nature,2006,441(7090): 235-238.
[5] Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america[J]. Clin Infect Dis,2010,50(3): 291-322.
[6] Charlier C, Nielsen K, Daou S,et al. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans[J]. Infect Immun, 2009,77(1): 120-127.
[7] Tan DB, Yong YK, Tan HY, et al. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis[J]. HIV Med,2008,9(5): 307-316.
[8] Schop J. Protective immunity against cryptococcus neoformans infection[J]. Mcgill J Med,2007,10(1): 35-43.
[9] Dardalhon V, Awasthi A, Kwon H, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells[J]. Nat Immunol,2008, 9(12): 1347-1355.
[10] Guzman-Fulgencio M, Jimenez JL, Berenguer J, et al. Plasma IL-6 and IL-9 predict the failure of interferon-alpha plus ribavirin therapy in HIV/HCV-coinfected patients[J]. J Antimicrob Chemother,2012,67(5): 1238-1245.
[11] Zelante T, De Luca A, Bonifazi P, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance[J]. Eur J Immunol,2007,37(10): 2695-2706.
[12] Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge[J]. Nat Immunol,2007,8(4): 369-377.
[13] Murdock BJ, Huffnagle GB, Olszewski MA,et al. Interleukin-17A Enhances Host Defense against Cryptococcal Lung Infection through Effects Mediated by Leukocyte Recruitment, Activation, and Gamma Interferon Production[J]. Infect Immun,2014, 82(3): 937-948.
[14] Beriou G, Bradshaw EM, Lozano E, et al. TGF-beta induces IL-9 production from human Th17 cells[J]. J Immunol,2010,185(1): 46-54.
[15] Nowak EC, Weaver CT, Turner H, et al. IL-9 as a mediator of Th17-driven inflammatory disease[J]. J Exp Med,2009,206(8): 1653-1660.
[16] Qiu Y, Davis MJ, Dayrit JK, et al. Immune modulation mediated by cryptococcal laccase promotes pulmonary growth and brain dissemination of virulent Cryptococcus neoformans in mice[J]. PLoS One,2012,7(10): e47853.
[17] Ye P, Garvey PB, Zhang P, et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection[J]. Am J Respir Cell Mol Biol,2001,25(3): 335-340.
[18] Turner JE, Morrison PJ, Wilhelm C, et al. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation[J]. J Exp Med,2013,210(13): 2951-2965.